Efficacy and Safety of TELMINUVO to Stage 2 Hypertension

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT01983735

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01983735
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01983735. Randomized; triple masking; primary purpose treatment. Start 2014-01 (registry gives no type); primary completion 2014-08 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of TELMINUVO to Stage 2 Hypertension
Condition
Hypertension
Intervention (Drug)
TELMINUVO Tab. (80/2.5mg)
Intervention (Drug)
TELMINUVO Tab. (80/5mg)
Intervention (Drug)
S-amlodipine 2.5mg
Intervention (Drug)
S-amlodipine 5mg
Lead sponsor
Chong Kun Dang Pharmaceutical (class: industry)

Record details

Record id
cardio:ct-nct01983735
Content hash
f787ad7a1b127e056f131ace175ec3895c16f418ff56d8848b19c4214e46e1be